HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Procter & Gamble

This article was originally published in The Rose Sheet

Executive Summary

Third quarter (ended March 31) sales were ahead 1.2% to $7.44 bil., the company announced April 27. Pretax profit increased 20% reflecting "our cost reduction programs along with solid unit volume gains in the U.S. and a continued double-digit volume growth rate in our international operations," the firm said. Excluding the impact of unusual terms -- a $102 mil. loss related to the close-out of two interest rate swap contracts during the recent three months and charges of $200 mil. and $925 mil. for the divestiture of P&G's juice business and changes in accounting standards, respectively, taken last year -- net earnings were up 16.3% to $584 mil. Including extraordinary items, net earnings fell 4% to $482 mil. A shareholder lawsuit related to the derivatives loss was filed April 26 in the Hamilton County Common Pleas Court in Ohio. The suit names several P&G executives. P&G announced the derivatives charge April 12 ("The Rose Sheet" April 18, in Brief)

Latest Headlines
See All
UsernamePublicRestriction

Register

RS000415

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel